These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28108196)

  • 21. Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study.
    Liguori C; Stefani A; Fernandes M; Cerroni R; Mercuri NB; Pierantozzi M
    J Parkinsons Dis; 2022; 12(2):537-544. PubMed ID: 34864690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical aids in the diagnosis of Parkinson's disease.
    Chase TN; Eng N; Gordon EK
    Ann Clin Lab Sci; 1976; 6(1):4-10. PubMed ID: 1247283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?
    Virameteekul S; Phokaewvarangkul O; Bhidayasiri R
    PLoS One; 2021; 16(12):e0261302. PubMed ID: 34937068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire.
    Pistacchi M; Gioulis M; Sanson F; Marsala SZ
    Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients].
    Krygowska-Wajs A; Szczudlik A; Antkiewicz-Michaluk L; Romańska I; Vetulani J
    Neurol Neurochir Pol; 1997; 31(5):875-85. PubMed ID: 9513952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetrahydrobiopterin and Parkinson's disease.
    Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
    Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
    Chia LG; Cheng FC; Kuo JS
    J Neurol Sci; 1993 Jun; 116(2):125-34. PubMed ID: 8336158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
    Goldstein DS; Holmes C; Lopez GJ; Wu T; Sharabi Y
    Parkinsonism Relat Disord; 2018 May; 50():108-112. PubMed ID: 29475591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease.
    Ishibashi K; Kanemaru K; Saito Y; Murayama S; Oda K; Ishiwata K; Mizusawa H; Ishii K
    Acta Neurol Scand; 2010 Jul; 122(1):46-51. PubMed ID: 20002007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid.
    Ebinger G; Michotte Y; Herregodts P
    J Neurochem; 1987 Jun; 48(6):1725-9. PubMed ID: 3572399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF homovanillic acid: an index of dopaminergic activity.
    Curzon G
    Adv Neurol; 1975; 9():349-57. PubMed ID: 125031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; De Bustos F; Zurdo M; Gómez-Escalonilla C; Barcenilla B; Berbel A; Camacho A; Arenas J
    J Neural Transm (Vienna); 2000; 107(4):445-9. PubMed ID: 11215755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
    Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
    Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in CSF biomarkers for Parkinson's disease.
    LeWitt P
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S49-51. PubMed ID: 22166453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.